Transcenta Announces Receipt of HiCB Out-Licensing Milestone Payment and Strong CDMO Business Momentum
Key Points:
- Milestone Payment Received: Transcenta Holding Limited has received a milestone payment of RMB 7 million through the out-licensing of its HiCB (highly intensified continuous bioprocessing) platform.
- Strategic Partnership Progress: The payment follows a strategic collaboration and non-exclusive licensing agreement with EirGenix Inc. (TWSE: 6589), executed in late 2025.
- GMP Production Implementation: Both companies achieved key technical milestones, moving towards implementing HiCB technology for GMP production at EirGenix’s facility.
- Leadership Appointment: Dr. Christopher Hwang, former CTO, has been appointed as Head of Global Partnerships for the HiCB platform to drive global out-licensing and commercialization.
- Steady CDMO Business Growth: Transcenta continues to expand its CDMO business, recently signing new GMP Drug Substance (DS) and Drug Product (DP) manufacturing contracts, including for complex biologics and siRNA projects.
- Ongoing Negotiations: The company is in discussion for further high-potential projects, including integrated IND development, additional siRNA GMP DP production, developability assessments, and material generation for global clients.
Details for Investors and Shareholders:
This announcement is potentially price sensitive as it demonstrates that Transcenta is successfully executing its commercialization and revenue strategy for the HiCB platform through milestone payments and non-exclusive licensing. This not only provides immediate cash inflow (RMB 7 million) but also paves the way for recurring revenue streams from licensing, service fees, and ongoing supply of culture media. The non-exclusive model preserves full technology ownership, allowing for additional future deals with other partners.
The appointment of Dr. Christopher Hwang to lead global partnerships underlines a commitment to accelerating the global rollout and revenue scaling of the HiCB platform. His expertise is expected to enhance the company’s ability to secure further licensing agreements and partnerships worldwide.
The CDMO (Contract Development and Manufacturing Organization) segment is also showing strong momentum, with new contracts in both DS and DP manufacturing, notably in high-growth areas like siRNA therapies. Ongoing negotiations for additional projects could further boost revenue and strengthen the company’s position in the global CDMO market.
The company notes that proceeds from these activities will be reinvested into further platform upgrades and core R&D activities, suggesting a virtuous cycle of innovation and growth.
Risks and Forward-Looking Statements: The announcement includes a caution that forward-looking statements are not guarantees of future performance and that financial data disclosed has not been audited. Investors are advised to exercise caution and seek professional advice when dealing in company shares.
Leadership and Governance:
- Board led by Dr. Xueming Qian (Executive Director, Chairman, CEO).
- Board also includes Dr. Li Xu (Non-Executive Director) and independent non-executive directors Mr. Jiasong Tang, Mr. Zhihua Zhang, Dr. Kumar Srinivasan, and Ms. Helen Wei Chen.
Potential Share Price Impact:
This news is likely to be viewed positively by the market, as it confirms the company’s ability to monetize its proprietary bioprocessing technology and expand its service offerings. The recurring revenue potential and progress in high-value CDMO contracts could drive a re-rating of the company’s valuation, especially if further deals are announced.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should exercise caution and consult professional advisors before making investment decisions.
